Patents Assigned to The Scripps Research Institute
  • Patent number: 11141385
    Abstract: This application describes a compound represented by Formula (I): wherein: Y is a biologically active organic core group comprising one or more of an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group, to which Z is covalently bonded; n is 1, 2, 3, 4 or 5; m is 1 or 2; Z is O, NR, or N; X1 is a covalent bond or —CH2CH2—, X2 is O or NR; and R comprises H or a substituted or unsubstituted group selected from an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group. Methods of preparing the compounds, methods of using the compounds, and pharmaceutical compositions comprising the compounds are described as well.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: October 12, 2021
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Jiajia Dong, K Barry Sharpless, Jeffery W. Kelly, Aleksandra Baranczak, Wentao Chen
  • Patent number: 11136370
    Abstract: In various embodiments, disclosed herein are assays for measuring thrombin generated (TG) in a blood sample, comprising: incubating the blood sample with TF, FIXa, and CaCl2; and measuring TG in the blood sample. Also disclosed herein are assays for determining a bleeding risk in a subject, comprising obtaining a blood sample from the subject; adding to the blood sample TF and/or FIXa; determining the amount of coagulation factor VIII (FVIII:C) in the blood sample; and determining (a) a mild bleeding risk in the subject if the amount of FVIII:C in the sample is >5 IU/dL, (b) a moderate bleeding risk in the subject if the amount of FVIII:C in the sample is 1-5 IU/dL, and (c) a severe bleeding risk in the subject if the amount of FVIII:C in the subject is <1 IU/dL.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: October 5, 2021
    Assignee: The Scripps Research Institute
    Inventors: Zaverio Ruggeri, Wolfram Ruf, Yuichi Kamikubo
  • Patent number: 11135186
    Abstract: The invention provides compounds for activating the activating transcription factor 6 (ATF6) arm of the unfolded protein response (UPR), or activating the transcriptional targets of ATF6, in the endoplasmic reticulum of a cell, the compounds being of any of formulas (I) through (IX) as described herein. The compounds can be used for treatment of conditions involving gain-of-toxic-function and loss-of-function folding disorders including lysosomal storage diseases, antitrypsin-associated emphysema and similar diseases. These molecules are also expected to have disease-ameliorating effects in Alzheimer's disease and diabetes.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: October 5, 2021
    Assignee: The Scripps Research Institute
    Inventors: Christina Cooley, Jeffery W. Kelly, Ryan Paxman, Lars Plate, R. Luke Wiseman
  • Patent number: 11124504
    Abstract: Compounds are provided that antagonize the kappa-opioid receptor (KOR) and products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof: wherein X, Y, R1, R2, R4, R5 R6, R7, R8 and R11 are as defined herein.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: September 21, 2021
    Assignees: THE SCRIPPS RESEARCH INSTITUTE, BLACKTHORN THERAPEUTICS, INC.
    Inventors: Edward Roberts, Miguel A. Guerrero, Mariangela Urbano, Hugh Rosen, Robert M. Jones, Candace Mae Laxamana, Xianrui Zhao, Eric Douglas Turtle
  • Publication number: 20210275664
    Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
    Type: Application
    Filed: March 8, 2021
    Publication date: September 9, 2021
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, The Scripps Research Institute, Trustees of Dartmouth College
    Inventors: Barney Graham, Jason McLellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
  • Patent number: 11104951
    Abstract: By a genome-wide gene analysis of expression profiles of known or putative gene sequences in peripheral blood and biopsy samples, the present inventors have identified a consensus set of gene expression-based molecular biomarkers for distinguishing liver transplantation patients who have Acute Rejection (AR), Hepatitis C Virus Recurrence (HCV-R), both AR/HCV-R, or Acute Dysfunction No Rejection (ADNR). These molecular biomarkers are useful for diagnosis, prognosis and monitoring of liver transplantation patients.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: August 31, 2021
    Assignees: The Scripps Research Institute, Northwestern University
    Inventors: Daniel Salomon, Josh Levitsky, Sunil Kurian, Michael Abecassis
  • Patent number: 11097002
    Abstract: The present invention provides novel nanoparticle presented vaccine compositions that are stabilized with a locking domain. Various immunogens can be employed in the preparation of the vaccine compositions, including viral immunogens such as HIV-1 and Ebola viral immunogens, and non-viral immunogens such as immunogens derived from bacteria, parasites and mammalian species. The invention also provides methods of using such vaccine compositions in various therapeutic applications, e.g., for preventing or treating viral infections.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: August 24, 2021
    Assignee: The Scripps Research Institute
    Inventors: Linling He, Jiang Zhu
  • Patent number: 11091546
    Abstract: Disclosed herein are chimeric antigen receptor effector cells (CAR-ECs) and CAR-EC switches. The switchable CAR-ECs are generally T cells. The one or more chimeric antigen receptors may recognize a peptidic antigen on the CAR-EC switch. The CAR-ECs and switches may be used for the treatment of a condition in a subject in need thereof.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: August 17, 2021
    Assignee: The Scripps Research Institute
    Inventors: Travis Young, David T. Rodgers, Ian Hardy, Chanhyuk Kim, Peter G. Schultz, Eric Hampton, Eduardo Laborda, Leonard Presta
  • Patent number: 11078273
    Abstract: The disclosure provides antibodies, antibody fragments or antigen-binding fragments, as well as related antibody drug conjugates (ADCs) and chimeric antigen receptors (CARs), that specifically recognize human ROR2, Also provided in the disclosure are methods of using such antibodies in various diagnostic and therapeutic applications.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: August 3, 2021
    Assignee: The Scripps Research Institute
    Inventors: Christoph Rader, Haiyong Peng, Xiuling Li
  • Patent number: 11078136
    Abstract: Provided is a process for converting an alkane to an alkene. The process comprises (a) contacting the alkane and either (i) an oxidizing electrophile comprising a main group element in oxidized form, or (ii) an oxidant and a reduced form of the oxidizing electrophile, in a liquid medium comprising an oxygen acid and optionally one or more additives selected from a non-oxidizable liquid, a salt additive, a Lewis acid, and water, to provide an oxidized intermediate and a reduced form of the oxidizing electrophile; (b) optionally separating the oxidized intermediate and the reduced form of the oxidizing electrophile; and (c) performing an elimination reaction on the oxidized intermediate to provide the alkene and the oxygen acid.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: August 3, 2021
    Assignees: The Scripps Research Institute, Hyconix, Inc.
    Inventors: Roy A. Periana, Brian G. Hashiguchi, Michael M. Konnick
  • Patent number: 11078235
    Abstract: The present invention concerns cyclic compounds, compositions comprising the cyclic compounds, linkers, a method of preparing a carrying agent:cyclic compound adduct, a method for treating disorders such as proliferation disorders (e.g., malignancies), bone deficiency diseases, and autoimmune diseases, and a method for suppressing the growth of, or inducing apoptosis in, cells (e.g., malignant cells).
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: August 3, 2021
    Assignees: H. Lee Moffitt Cancer Center And Research Institute, Inc., The Scripps Research Institute, University of South Florida
    Inventors: Lori Hazlehurst, Christoph Rader, Xiuling Li, Mark McLaughlin
  • Patent number: 11066398
    Abstract: This invention provides small molecule Myc-inhibitors. Also provided in the invention are therapeutic applications of these compounds for treating Myc-driven cancer and other related methods.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: July 20, 2021
    Assignees: The Scripps Research Institute, Sorrento Therapeutics, Inc.
    Inventors: Peter K. Vogt, Francis X. Tavares, Kim D. Janda
  • Publication number: 20210196713
    Abstract: The present disclosure provides compounds, their pharmaceutical compositions, and methods of their use for treating mesenchymally-derived or mesenchymally transformed cancers, such as breast cancers and sarcomas, and for treating diseases or disorders that are characterized by the expression of vimentin.
    Type: Application
    Filed: October 30, 2018
    Publication date: July 1, 2021
    Applicants: The Scripps Research Institute, Board of Regents, The University of Texas System
    Inventors: Luke L. Lairson, Michael J. Bollong, Peter G. Schultz, Sendurai A. Mani
  • Patent number: 11045476
    Abstract: Described herein are compounds and compositions for the amelioration of arthritis or joint injuries by inducing mesenchymal stem cells into chondrocytes.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: June 29, 2021
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Peter G. Schultz, Arnab K. Chatterjee, Shoutian Zhu, Joshua Payette, Hongchul Yoon, Baiyuan Yang
  • Patent number: 11046933
    Abstract: The slow kinetics and low efficiency of reprogramming methods to generate human induced pluripotent stem cells (iPSCs) impose major limitations on their utility in biomedical applications. Here we describe a chemical approach that dramatically improves (>200 fold) the efficiency of iPSC generation from human fibroblasts, within seven days of treatment. This will provide a basis for developing safer, more efficient, non-viral methods for reprogramming human somatic cells.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: June 29, 2021
    Assignee: The Scripps Research Institute
    Inventors: Tongxiang Lin, Sheng Ding
  • Patent number: 11040959
    Abstract: A diprovocim compound that corresponds in structure to structural Formula V is disclosed, wherein A, W, Z, R1, R2, R3 and R4 (when present) are defined within. A diprovocim compound has immune-adjuvant properties on human and mouse cells in culture and on in vivo immunization of mice. A composition containing a diprovocim and a method of using a compound are also disclosed. The immunostimulatory activity of a diprovocim compound is similar to that of LPS, to which there is no apparent structural similarity. A contemplated compound bears no structural similarity to either the TLR1/TLR2 lipoprotein agonists nor to any other synthetic TLR agonist, and is remarkably easy to prepare and synthetically modify.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: June 22, 2021
    Assignees: The Board of Regents of the University of Texas System, The Scripps Research Institute
    Inventors: Bruce Beutler, Dale L. Boger
  • Patent number: 11034691
    Abstract: The invention provides compounds effective as sphingosine-1-phosphate receptor modulators for treatment of cardiopulmonary diseases, such as hypertension (including malignant hypertension), angina, myocardial infarction, cardiac arrhythmias, congestive heart failure, coronary heart disease, atherosclerosis, angina pectoris, dysrhythmias, cardiomyothopy (including hypertropic cardiomyothopy), heart failure, cardiac arrest, bronchitis, asthma, chronic obstructive pulmonary disease, cystic fibrosis, croup, emphysema, pleurisy, pulmonary fibrosis, pneumonia, pulmonary embolus, pulmonary hypertension, mesothelioma, ventricular conduction abnormalities, complete heart block, adult respiratory distress syndrome, sepsis syndrome, idiopathic pulmonary fibrosis, scleroderma, systemic sclerosis, retroperitoneal fibrosis, prevention of keloid formation, or cirrhosis.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: June 15, 2021
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Edward Roberts, Hugh Rosen, Mariangela Urbano, Miguel Guerrero
  • Publication number: 20210163503
    Abstract: Provided is an oxidizing composition, in which a liquid medium is substantially inert in the presence of an oxidizing electrophile contained in the liquid medium. The composition comprises (a) an oxidizing electrophile comprising a main group element in oxidized form and at least one conjugate anion of an oxygen acid; (b) a non-oxidizable liquid selected from a fluorinated hydrocarbon, a sulfone, a deactivated arene, a deactivated aliphatic, a deactivated heteroarene, a deactivated heteroaliphatic, and a combination thereof; and (c) optionally one or more salt additives. Further provided are a method of using the oxidizing composition to oxidize a substrate and a method of generating and/or regenerating an oxidizing electrophile comprising a main group element.
    Type: Application
    Filed: May 25, 2018
    Publication date: June 3, 2021
    Applicants: The Scripps Research Institute, Hyconix, Inc.
    Inventors: Roy A. PERIANA, Brian G. HASHIGUCHI, Michael M. KONNICK
  • Patent number: 11021453
    Abstract: This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for a method of treating a patient in need thereof, where the patient is suffering from post-traumatic stress disorder comprising administering a disclosed compound or composition.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: June 1, 2021
    Assignees: LUNDBECK LA JOLLA RESEARCH CENTER, INC., THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Justin S. Cisar, Cheryl A. Grice, Todd K. Jones, Micah J. Niphakis, Jae Won Chang, Kenneth M. Lum, Benjamin F. Cravatt
  • Patent number: 11021427
    Abstract: The invention includes procedures for stereoselective ?-acylation of carboxylic acids having a ?-carbon atom.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: June 1, 2021
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Jin-Quan Yu, Pengxiang Shen